Respiratory Syncytial Virus Vaccine and Nirsevimab Uptake Among Pregnant People and Their Neonates
- Christine Blauvelt; Molly Zeme; Aishwarya Natarajan; Adrienne Epstein; Michelle Roh; Amayrani Morales
 
Access Resources
About
                This study was conducted to describe the uptake of the prenatal RSVpreF vaccine and infant nirsevimab during the 2023-2024 RSV season. It found high uptake of both the RSVpreF vaccine and nirsevimab, with nirsevimab being administered even to those who did not receive routine vaccines. The research showed no significant link between RSVpreF vaccination and preterm birth, indicating that a prevention strategy combining prenatal vaccination and infant monoclonal antibody had good uptake and positive perinatal outcomes.
              
            Tags
More like this
            The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.